Novel insights into the pathogenesis and treatment of NRAS mutant melanoma
- 11 August 2021
- journal article
- other
- Published by Taylor & Francis in Expert Review of Precision Medicine and Drug Development
- Vol. 6 (4) , 281-294
Abstract
Introduction: NRAS was the first mutated oncogene identified in melanoma and is currently the second most common driver mutation in this malignancy. For patients with NRASmutant advanced stage melanoma refractory to immunotherapy or with contraindications to immune-based regimens, there are few therapeutic options including low-efficacy chemotherapy regimens and binimetinib monotherapy. Here, we review recent advances in preclinical studies of molecular targets for NRAS mutant melanoma as well as the failures and successes of early-phase clinical trials. While there are no targeted therapies for NRAS-driven melanoma, there is great promise in approaches combining MEK inhibition with inhibitors of the focal adhesion kinase (FAK), inhibitors of autophagy pathways, and pan-RAF inhibitors. Areas Covered: This review surveys new developments in all aspects of disease pathogenesis and potential treatment – including those that have failed, stalled, or progressed through various phases of preclinical and clinical development. Expert Opinion: There are no currently approved targeted therapies for BRAF wild-type melanoma patients harboring NRAS driver mutations though an array of agents are in early phase clinical trials. The diverse strategies taken exploit combined MAP kinase signaling blockade with the inhibition of cell cycle mediators, inhibition of the autophagy pathway, and alteration of kinases involved in actin cytoskeleton signaling. Future advances of developmental therapeutics into late stage trials may yield new options beyond immunotherapy for patients with advanced stage disease and NRAS mutation status.Keywords
Funding Information
- NIH/NCI (1R01CA227481)
- James C. Bradford Jr. Melanoma Fund
- Incyte
- Melanoma Research Foundation
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (1R61AR076824-01)
- National Cancer Institute (1R01CA250101-01)
- NeoImmuneTech, Inc
- Amphivena Therapeutics, Inc
- Bristol-Myers Squibb
- Corvus Pharmaceuticals, Inc
- Covance Inc
- Nektar Therapeutics
- Calithera Biosciences
- Hoosier Cancer Research Network, Inc
- DrugDev Inc
- Merck Sharp & Dohme Corporation (KEB)
- BMS-IASLC-LCF
This publication has 157 references indexed in Scilit:
- Multiple Congenital Melanocytic Nevi and Neurocutaneous Melanosis Are Caused by Postzygotic Mutations in Codon 61 of NRASJournal of Investigative Dermatology, 2013
- A Landscape of Driver Mutations in MelanomaCell, 2012
- MITF-siRNA Formulation Is a Safe and Effective Therapy for Human MelasmaMolecular Therapy, 2011
- High Frequency of p16 Promoter Methylation in NRAS-Mutated Cutaneous MelanomaJournal of Investigative Dermatology, 2010
- Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticlesNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- The cancer genomeNature, 2009
- Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body siteMolecular Oncology, 2007
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Mutations of the BRAF gene in human cancerNature, 2002